KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Payables (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Payables for 13 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Payables fell 23.37% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, down 23.37% year-over-year, with the annual reading at $3.9 million for FY2025, 23.37% down from the prior year.
  • Payables for Q4 2025 was $3.9 million at Xenon Pharmaceuticals, down from $4.6 million in the prior quarter.
  • The five-year high for Payables was $31.6 million in Q2 2025, with the low at $1.7 million in Q1 2022.
  • Average Payables over 5 years is $13.1 million, with a median of $10.6 million recorded in 2021.
  • The sharpest move saw Payables surged 1183.73% in 2023, then plummeted 80.48% in 2024.
  • Over 5 years, Payables stood at $13.7 million in 2021, then surged by 61.95% to $22.2 million in 2022, then increased by 16.93% to $26.0 million in 2023, then tumbled by 80.48% to $5.1 million in 2024, then dropped by 23.37% to $3.9 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $3.9 million, $4.6 million, and $31.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.